Theranostic PET for target validation and tumor detection in solid cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Patients undergoing theranostic PET scans as part of routine cancer care are enrolled to collect data on how well PET tracer uptake matches molecular target expression, how often tumor regions show uptake, and how PET findings influence clinical decisions. The study analyzes diagnostic performance metrics such as sensitivity, specificity, PPV, and detection rate, using both PET/CT and PET/MRI with novel or established tracers. Primary endpoint examines the association between PET uptake intensity and histopathologic target expression. Secondary endpoints cover per-lesion uptake, regional and patient-level detection, and changes in staging or prognosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. PET imaging with a theranostic PET tracer scheduled for staging or restaging of tumor types as part of clinical routine
2. Age ≥ 18 years

Exclusion Criteria:

1. Patient cannot give consent for the study
2. Patient cannot lie flat or tolerate PET imaging
3. Unwillingness or inability to comply with study and follow-up procedures
4. Condition of patient which is critical to participate in this study in the discretion of the investigators
5. Pregnant, lactating, or breast-feeding women

Where it's running

• University Hospital Essen
  Essen, Germany Recruiting

Study contacts

• Principal investigator: David Kersting, MD PhD — University Hospital, Essen
• Study coordinator: Josephine Enste
• Email: josephine.enste@uk-essen.de
• Phone: +492017232073

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cold exposure with PD-1/PD-L1 immunotherapy in solid tumors

  This phase 1 study tests whether adding controlled cold exposure to standard PD-1/PD-L1 therapy is safe and feasible in adults with solid tumors.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07538479

• 177Lu-IM-3050, a targeted radiopharmaceutical for advanced solid tumors.

  This trial will test whether the targeted radioactive drug 177Lu-IM-3050 is safe and can shrink FAP-positive advanced solid tumors in adults who have not responded to standard treatments.

  Recruiting at 5 sites Phase 1 Immunome, Inc. · Dothan, Alabama and 4 other locations · NCT07505771

• CMAB017 for safety and tolerability in advanced solid tumors

  This trial tests whether the experimental antibody CMAB017 is safe and tolerated in adults with advanced solid tumors who have exhausted or declined standard treatments.

  Recruiting Phase 1 Taizhou Mabtech Pharmaceutical Co.,Ltd · Shanghai · NCT06933069

• Testing IM-1021 for advanced cancer treatment

  This study is testing a new treatment called IM-1021 to see if it can safely help people with advanced cancer feel better.

  Recruiting at 24 sites Phase 1 Immunome, Inc. · Duarte, California and 23 other locations · NCT06823167

• SKB571 for adults with advanced solid tumors

  This first-in-human Phase 1 test gives SKB571 to adults with advanced or metastatic solid tumors to see if it is safe, how the body handles it, and whether it shows anti-tumor activity.

  Recruiting at 13 sites Phase 1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Guangzhou, Guangdong and 14 other locations · NCT06725381

• Exploring a new imaging tracer for cancer detection

  This study is testing a new imaging tracer to see if it can help doctors find cancer in patients with tumors using special scans.

  Recruiting Affiliated Hospital of Jiangnan University · Wuxi, Jiangsu · NCT06684028

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.